Subscribe
Date
Past
2012
2013
2014
2015
2016
2017
2018
2019
Upcoming

Building a Zika virus vaccine

From global health to virus–like particle technology

2/14/2019

Velasco Cimica, Ph.D., is an expert in vaccine development using virus-like particles for developing vaccine candidates for emerging viruses. Join this webinar to hear Dr. Cimica cover the following key points:

  • We have developed a chimeric Zika-VLP–based vaccine that elicits a protective immune response and prevents antibody-dependent enhancement (ADE) and Guillian Barré Syndrome (GBS) in murine animal models. 
  • Zika-VLPs containing the CD loop sub-structural domain from envelope protein domain III induced a strong antibody response against the Zika virus in mouse models after prime immunization. 
  • The protective immunity of our novel Zika-VLP vaccine candidates is mediated by antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.